Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
Go back to Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.59 | 52 Week High | $333.65 | |||
| Open | $199.59 | 52 Week Low | $223.02 | |||
| Day High | $199.59 | P/E | 25.56 | |||
| Day Low | $199.59 | EPS | $7.81 | |||
| Volume | 191 | |||||
